Ketamine + Mindfulness for Depression
Completed
In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the conjunction of ketamine + mindfulness enhances the reductions in depression following a single ketamine infusion.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/30/2024
Locations: Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania
Conditions: Depression, Unipolar
Repeated Neurocognitive Measurements in Depressed Patients
Completed
In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/30/2024
Locations: Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania
Conditions: Depression, Unipolar
Ketamine HCl Prolonged Release Oral Tablets for CRPS
Not Yet Recruiting
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic profile of Ketamine HCl Prolonged Release (PR) tablets in participants with pain due to complex regional pain syndrome (CRPS). Additionally, this trial will explore the feasibility of the trial design through dosing compliance, clinical instruments, and efficacy signals.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/25/2024
Locations: Pain Center, Keck Medical Center of University of Southern California, Los Angeles, California
Conditions: Complex Regional Pain Syndromes
Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot
Terminated
This project seeks to identify the acute and longer-term impact of a single dose of intravenous ketamine among suicidal patients referred for psychiatric consultation/liaison in the medical inpatient setting. The investigators will then test whether ketamine's rapid effects can be extended by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat suicidality more efficiently and with broader dissemination by rapidl... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/18/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Suicide, Attempted
Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
Suspended
Changes in the communication of glutamate from one brain structure to another are important in the development of therapy for cocaine use disorders. Our preliminary investigations suggest that drugs that affect glutamate exchange may be effective at promoting and maintaining individuals' abstinence from cocaine. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) and mindfulness based re... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/12/2024
Locations: NYSPI, New York, New York
Conditions: Cocaine Use Disorder
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Active Not Recruiting
Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior. The purpose of this randomized, double-blind, controlled trial is to test the efficacy of a glutamate modulator among PASC patients suffering from new-onset or worsening of depressive symptoms.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/12/2024
Locations: New York State Psychiatric Institute, New York, New York
Conditions: Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction
Stanford Regulating Circuits of the Brain Study- Ketamine
Completed
This study is a biomarker study designed to characterize how ketamine impacts the reward circuits of the human brain.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/05/2024
Locations: Stanford Psychiatry, Palo Alto, California
Conditions: Healthy
Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus
Completed
Tinnitus, or ringing in the ears, is a very common problem that often accompanies hearing loss. It affects up to 1 in 10 adults, and about 30% of people who experience chronic tinnitus find it very distressing. In these patients, symptoms of depression and anxiety often accompany tinnitus and there are no approved treatments. Clinical trials are ongoing to test a glutamate NMDA receptor antagonist (called esketamine), which is injected into the inner ear. However, the preliminary results with th... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
07/01/2024
Locations: 1051 Riverside Drive, New York, New York
Conditions: Tinnitus
IN Midazolam vs IN Dexmedetomidine vs IN Ketamine During Minimal Procedures in Pediatric ED
Recruiting
Pain in young children has been universally under-recognized due to their inability to describe or localize pain. Improvements in pharmacological interventions are necessary to optimize patient and family experience and allow for successful and efficient procedure completion. This is the first study that will compare three intranasal medications (Intranasal Midazolam, Dexmedetomidine, and Ketamine) to evaluate the length of stay after medication administration along with patient and provider sat... Read More
Gender:
ALL
Ages:
Between 1 year and 5 years
Trial Updated:
06/26/2024
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Laceration of Skin, Anxiety, Discharge Time
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Recruiting
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relativ... Read More
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
06/24/2024
Locations: Wells Medicine, Houston, Texas +1 locations
Conditions: Healthy, Major Depressive Disorder, Treatment Resistant Depression
A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain
Completed
Acute Pain is one of the most frequent chief complaints and the main reason for visiting the Emergency Department (ED). The acute pain in the ED is largely prevalent across the country with recent literature demonstrating that 61-91% of patients are admitted to the ED due to a variety of acute painful syndromes. There is a lack of good options for pain control in such settings.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/20/2024
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Pain
Comparison of Nebulized Ketamine to Intravenous Sub-Dissociative Dose Ketamine for Pain
Completed
Ketamine is a non-competitive N-methyl-D-aspartate (NMDA)/glutamate receptor complex antagonist that decreases pain by diminishing central sensitization, hyperalgesia, and "wind-up" phenomenon at the level of the spinal cord (dorsal ganglion) and central nervous system (1). Ketamine administration in sub-dissociative doses (SDK) of 0.1-0.3 mg/kg in pre-hospital settings and in the ED results in effective pain relief in patients with acute traumatic and non-traumatic pain, chronic non-cancer and... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/10/2024
Locations: Maimonides Medical Center, Brooklyn, New York
Conditions: Pain